Pharmacogenetics is the study of how an individual's genetic makeup impacts their response to medications. It considers how well medicines work and what side effects may occur based on a person's genes. Pharmacogenetics aims to develop personalized medicine by tailoring drug selection and dosages to a patient's genetic profile to maximize effectiveness and minimize adverse reactions. Current applications include determining drug responses for cardiac, respiratory, and psychiatric conditions.
Clinical research involves investigating investigational products in human subjects to discover or verify their clinical, pharmacological, and toxic effects. Clinical trials help translate basic scientific research into better ways to prevent, diagnose, or treat disease. Conducting clinical research in pediatric populations requires special considerations due to important developmental differences compared to adults. Key areas of difference include organ maturation, drug absorption, distribution, metabolism, and elimination, which can vary significantly across pediatric age groups from neonates to adolescents. Informed consent from parents or guardians is required. Clinical trials in pediatrics aim to establish safe and effective treatments while minimizing risk.
The document discusses factors that can modify drug effects, including individual differences in pharmacokinetics, receptors, and physiological states. It describes several factors such as body size, age, sex, genetics, disease states, and other drugs that can impact drug response either quantitatively by altering concentrations or qualitatively by changing the type of response. Understanding these modifying factors is important for physicians to consider when determining individualized drug dosing and avoiding adverse reactions.
This document defines drug interactions and describes the main types including drug-drug, drug-food, drug-disease, and drug-laboratory test interactions. It explains that interactions occur via changes to a drug's pharmacokinetics or pharmacodynamics. The major mechanisms of drug-drug interactions are pharmaceutical interactions when drugs are mixed, and pharmacokinetic interactions which influence absorption, distribution, metabolism, or excretion of a drug. Pharmacodynamic interactions can be direct, acting on the same site, or indirect through other body systems. Factors that increase risk of interactions and strategies to reduce interactions are also outlined.
This document provides an overview of addiction and pregnancy, including:
- Rates of drug and alcohol use during pregnancy range from 12-24% and pose risks to fetal development.
- Treatment includes medication-assisted therapy with methadone or buprenorphine, which can improve outcomes compared to untreated addiction.
- Babies exposed to opioids in utero may develop neonatal abstinence syndrome requiring supportive care and sometimes pharmacological treatment.
This document discusses dosing considerations for vulnerable patient populations including pregnant women, children, elderly patients, and those with organ impairments or weight abnormalities. It notes several groups are at high risk for adverse drug reactions and require careful dosing. Factors like developmental stage, organ function changes, body composition, and concurrent illnesses must be considered to safely and effectively treat these patients.
This document provides an introduction to the field of pharmacology. It defines pharmacology as the study of drug action, including their origins, properties, and interactions with living organisms. The document then discusses several key areas within pharmacology, including clinical pharmacology, neuropharmacology, psychopharmacology, and pharmacokinetics. It also defines important terms like drugs, medicines, pro-drugs, and the four main processes involved in pharmacokinetics - absorption, distribution, metabolism, and excretion (ADME).
This document discusses pharmacogenomics, which is the study of how an individual's genetic makeup affects their response to drugs. It explains that people can metabolize and respond to drugs differently due to genetic variations. The goal of pharmacogenomics is to optimize drug therapy for each individual by selecting the right drug, dose, and time based on their genotype to maximize effectiveness and minimize side effects. It outlines how variations can influence whether receptors are present to bind drugs, other physiological traits, and how the body processes drugs through absorption, distribution, metabolism and excretion.
Clinical research involves investigating investigational products in human subjects to discover or verify their clinical, pharmacological, and toxic effects. Clinical trials help translate basic scientific research into better ways to prevent, diagnose, or treat disease. Conducting clinical research in pediatric populations requires special considerations due to important developmental differences compared to adults. Key areas of difference include organ maturation, drug absorption, distribution, metabolism, and elimination, which can vary significantly across pediatric age groups from neonates to adolescents. Informed consent from parents or guardians is required. Clinical trials in pediatrics aim to establish safe and effective treatments while minimizing risk.
The document discusses factors that can modify drug effects, including individual differences in pharmacokinetics, receptors, and physiological states. It describes several factors such as body size, age, sex, genetics, disease states, and other drugs that can impact drug response either quantitatively by altering concentrations or qualitatively by changing the type of response. Understanding these modifying factors is important for physicians to consider when determining individualized drug dosing and avoiding adverse reactions.
This document defines drug interactions and describes the main types including drug-drug, drug-food, drug-disease, and drug-laboratory test interactions. It explains that interactions occur via changes to a drug's pharmacokinetics or pharmacodynamics. The major mechanisms of drug-drug interactions are pharmaceutical interactions when drugs are mixed, and pharmacokinetic interactions which influence absorption, distribution, metabolism, or excretion of a drug. Pharmacodynamic interactions can be direct, acting on the same site, or indirect through other body systems. Factors that increase risk of interactions and strategies to reduce interactions are also outlined.
This document provides an overview of addiction and pregnancy, including:
- Rates of drug and alcohol use during pregnancy range from 12-24% and pose risks to fetal development.
- Treatment includes medication-assisted therapy with methadone or buprenorphine, which can improve outcomes compared to untreated addiction.
- Babies exposed to opioids in utero may develop neonatal abstinence syndrome requiring supportive care and sometimes pharmacological treatment.
This document discusses dosing considerations for vulnerable patient populations including pregnant women, children, elderly patients, and those with organ impairments or weight abnormalities. It notes several groups are at high risk for adverse drug reactions and require careful dosing. Factors like developmental stage, organ function changes, body composition, and concurrent illnesses must be considered to safely and effectively treat these patients.
This document provides an introduction to the field of pharmacology. It defines pharmacology as the study of drug action, including their origins, properties, and interactions with living organisms. The document then discusses several key areas within pharmacology, including clinical pharmacology, neuropharmacology, psychopharmacology, and pharmacokinetics. It also defines important terms like drugs, medicines, pro-drugs, and the four main processes involved in pharmacokinetics - absorption, distribution, metabolism, and excretion (ADME).
This document discusses pharmacogenomics, which is the study of how an individual's genetic makeup affects their response to drugs. It explains that people can metabolize and respond to drugs differently due to genetic variations. The goal of pharmacogenomics is to optimize drug therapy for each individual by selecting the right drug, dose, and time based on their genotype to maximize effectiveness and minimize side effects. It outlines how variations can influence whether receptors are present to bind drugs, other physiological traits, and how the body processes drugs through absorption, distribution, metabolism and excretion.
This document provides information about Morwenna Given and her medical herbalism practice. She combines holistic treatment with the healing properties of plants to help people achieve optimal health. Her training includes 6 years of university, hospital, and clinical settings in herbal medicine, pharmacology, and working with conventional medicine. Plant medicine has been shown to be safe and effective for treating conditions like depression and anxiety by addressing biochemical imbalances and hormonal issues through adaptogens, nervines, and bitters. The document outlines treatment approaches involving herbal compounds and lifestyle changes to treat the underlying causes of issues rather than just the symptoms.
- Pharmacogenomics deals with how genetic variations influence individual responses to drugs in terms of efficacy and toxicity. It aims to identify individuals who are more or less likely to respond to drugs or require altered doses.
- Pharmacogenetics studies variations in targeted genes or related genes, while pharmacogenomics uses genetic information to guide individualized drug and dose choice.
- Genetic polymorphisms like SNPs can result in different amino acids, protein changes, or no effect. They influence drug metabolism and response.
- Pharmacogenomics offers advantages like personalized medicine but faces barriers like complexity, education needs, and drug company incentives. It is being applied in various stages of clinical trials from target identification to dosing.
This document discusses personalized medicine (PM), which aims to provide customized treatment and care based on a patient's genetic profile. PM considers how genetic variations affect an individual's response to medications and susceptibility to diseases. The document outlines key benefits of PM, such as improved medication selection and safer dosing to minimize adverse reactions. It also discusses some current genetic tests used in PM, such as tests for enzymes involved in drug metabolism. Overall, the document presents PM as a promising approach that may enable more effective, targeted treatment tailored to individual patients.
Introduction to Pharmacology & ToxicologyNisha Mhaske
This document defines key terms related to pharmacology including:
- Pharmacy deals with the preparation of drugs for administration. Pharmacology is the study of drugs, their mechanisms and effects. Pharmacokinetics studies what the body does to drugs and pharmacodynamics studies what drugs do to the body. Other terms defined include bioavailability, pharmacogenetics, xenobiotics, orphan drugs, branded vs generic drugs, patents, and half-life.
The document discusses the role of genomics in pharmacogenomics and drug development. It defines key terms like pharmacogenomics and pharmacogenetics. It explains how genomics technologies can help optimize drug efficacy and minimize toxicity by identifying genetic variations that influence individual drug responses. Genomic information from the human genome project can aid drug target identification and reduce bottlenecks in development. Single nucleotide polymorphisms are discussed as the most common genetic variations affecting drug metabolism. The applications of pharmacogenomics in precision medicine to improve drug safety and efficacy are summarized.
THE PURPOSE of the following sections is to give a brief description of many of the major drug classes that are important to nursing pharmacology; for drug class, we ‘ll discuss one prototype drug and examine it for information about warnings, indications, administration, and more; nurses, however, should seek out detailed information about individual drugs, as the prototype cannot be assumed to provide comprehensive information on other drugs in the same class; underline=preferred administration route
This document summarizes key points about pharmacology and drug use during pregnancy. It discusses how drugs can potentially harm the fetus, especially during organogenesis in the first trimester. Certain drugs like alcohol and cigarettes are definitely teratogenic. Most small drugs pass through the placenta. The document then covers organogenesis, fetal development, delivery, recognizing teratogenic drugs, and provides guidance on commonly used drug classes in pregnancy like analgesics, antibiotics, anti-epileptics, and cardiovascular drugs.
This document discusses addictive behavior and the neurobiology of addiction. It defines addictive behavior as compulsive drug use despite negative consequences and craving effects beyond pain relief. It describes how drugs of abuse hijack the brain's reward system and lead to long-term changes in gene expression and neural plasticity through mechanisms like conditioning and memory formation. These changes help explain why addiction is persistent and why drug cues can trigger intense craving and relapse. The neurobiology of addiction involves dysregulation of the dopamine and other neurotransmitter systems in the brain's reward pathways.
Pharmacology for Physiotherapy Book By Padmaja Udaykumar Second Edition.Khalid Ghaznavi
Pharmacology for Physiotherapy Book
By Padmaja Udaykumar Second Edition.
This consists of a complete book version. I hope this will be helpful for you.
This document summarizes a systematic review that analyzed randomized controlled drug trials for fibromyalgia syndrome (FMS) and painful diabetic peripheral neuropathy (DPN) to determine the impact of nocebo effects on adverse events reported. The review found that nocebo effects substantially accounted for adverse events in the drug groups for both conditions. Specifically, nocebo effects accounted for 72.0% of dropouts due to adverse events in the FMS drug groups and 44.9% in the DPN drug groups. The review calls for standards to better assess and report adverse events in clinical trials to more accurately determine the risks and benefits of drug therapies.
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
This document defines adverse drug reactions and discusses their types, causes, manifestations, and prevention. It provides classifications of ADRs including Type A predictable reactions related to the drug's pharmacological effects and Type B unpredictable reactions like allergies. The document outlines various organ-specific ADRs and roles of pharmacists in monitoring ADRs. It emphasizes the importance of pharmacovigilance in detecting, understanding, and preventing adverse drug effects.
Drug standards and legislation are governed by laws in every country. Internationally, the first law to regulate drugs was passed in 1906 requiring drugs be free of adulterants. The Food, Drug and Cosmetic Act of 1938 required all drugs be tested for safety and approved by the FDA for marketing. The Kefauver-Harris Amendments of 1962 were passed after thalidomide caused birth defects, requiring increased drug testing. In Pakistan, several acts have been passed over time to regulate drugs including the Poisonous Act of 1919, Dangerous Drugs Act of 1930, and Pharmacy Act of 1967. The Drug Act of 1976 regulates the pharmaceutical industry and drug quality and safety.
This document provides an overview of homeopathy, including its history, mechanisms, research evidence, and applications for issues related to lactation and pediatrics. It discusses Samuel Hahnemann's development of homeopathy in the 18th century, various hypotheses for its mechanisms of action, research on its effects in animals and humans, and some studies on its use for acute infections, mastitis, gastrointestinal issues, and lactation pain in children and animals.
This document discusses drug therapy in geriatrics. It begins by listing common drug classes used to treat various conditions in elderly patients, including antibiotics, antiallergics, antiasthmatics, and antihypertensives. It then discusses several age-related changes to pharmacokinetic and pharmacodynamic processes in geriatric patients. These changes can impact drug absorption, distribution, metabolism, and excretion. It also notes an increased risk of drug interactions and adverse reactions in elderly patients due to polypharmacy and physiological changes. Finally, it discusses the role of pharmacists in optimizing drug therapy for geriatric patients.
PERSONALIZED MEDICINE AND PHARMACOGENETICSAravindgowda6
This document discusses personalized medicine and pharmacogenetics. It defines personalized medicine as tailoring medical treatment to an individual's characteristics. Pharmacogenetics is the study of how genetic differences influence variability in drug responses. The document outlines how genetic polymorphisms can impact drug metabolism and efficacy through variations in phase I and phase II drug metabolizing enzymes. It also categorizes different types of patients who may benefit from personalized medicine approaches based on factors like age, gender, medical conditions, and genetics.
The document discusses important considerations for pediatric drug handling. It covers pharmacokinetic parameters like absorption, distribution, metabolism, and excretion that differ in children compared to adults due to developmental changes. The document emphasizes the need for pediatric clinical trials to determine appropriate drug dosages, formulations, and administration methods for children of different ages. Monitoring growth, vital signs, and laboratory parameters is also important for safe drug therapy in children.
Pharmacogenomics- a step to personalized medicinesApusi Chowdhury
Pharmacogenomics aims to optimize drug therapy based on a patient's genotype to maximize efficacy and minimize adverse effects. It involves studying how genetic factors influence individual responses to drugs in terms of absorption, distribution, metabolism, and excretion. Genetic polymorphisms like SNPs that occur in over 1% of the population can impact a drug's effects. Pharmacogenomic testing identifies biomarkers related to drug metabolism and targets to determine effective treatments and dosages for patients. While it holds promise for improving drug development and personalized medicine, limitations include insufficient validation and high costs.
The document discusses key concepts related to pharmaceutical dosage forms including:
1) It defines drug and dosage form, noting that dosage form denotes the method of delivery into the biological system.
2) It explains that most drugs are not administered in pure form, but are converted into suitable preparations using excipients before being given to patients.
3) The importance of choosing the proper dosage form is that it affects how the drug is administered and how effectively it can treat a medical condition.
The document discusses brain tonics and their use in improving memory and brain function. It defines brain tonics as natural remedies that improve concentration, mood, and memory problems. Brain tonics contain herbs that enhance neurotransmitters and improve blood flow to the brain, supplying nutrients. They are useful for conditions like Alzheimer's disease and lack of concentration. Alzheimer's causes memory loss and other cognitive issues due to plaques and tangles damaging brain cells. Brain tonics support brain health and function by promoting cellular equilibrium in the nervous system.
This document discusses the role of automation and robotics in the drug discovery process. It outlines how robotics are used at various stages including screening compound collections, chemical synthesis, and purification. The use of robotics allows for faster, more consistent, and more cost-effective experimentation. It enables high-throughput experimentation by automating repetitive tasks, improving yields, and allowing scientists to synthesize and purify thousands of compounds. The key types of industrial robots used are Cartesian, SCARA, and articulated robots, each with advantages for different applications. Automation has significantly improved the drug discovery process by enhancing reproducibility, purity and efficiency.
This document provides information about Morwenna Given and her medical herbalism practice. She combines holistic treatment with the healing properties of plants to help people achieve optimal health. Her training includes 6 years of university, hospital, and clinical settings in herbal medicine, pharmacology, and working with conventional medicine. Plant medicine has been shown to be safe and effective for treating conditions like depression and anxiety by addressing biochemical imbalances and hormonal issues through adaptogens, nervines, and bitters. The document outlines treatment approaches involving herbal compounds and lifestyle changes to treat the underlying causes of issues rather than just the symptoms.
- Pharmacogenomics deals with how genetic variations influence individual responses to drugs in terms of efficacy and toxicity. It aims to identify individuals who are more or less likely to respond to drugs or require altered doses.
- Pharmacogenetics studies variations in targeted genes or related genes, while pharmacogenomics uses genetic information to guide individualized drug and dose choice.
- Genetic polymorphisms like SNPs can result in different amino acids, protein changes, or no effect. They influence drug metabolism and response.
- Pharmacogenomics offers advantages like personalized medicine but faces barriers like complexity, education needs, and drug company incentives. It is being applied in various stages of clinical trials from target identification to dosing.
This document discusses personalized medicine (PM), which aims to provide customized treatment and care based on a patient's genetic profile. PM considers how genetic variations affect an individual's response to medications and susceptibility to diseases. The document outlines key benefits of PM, such as improved medication selection and safer dosing to minimize adverse reactions. It also discusses some current genetic tests used in PM, such as tests for enzymes involved in drug metabolism. Overall, the document presents PM as a promising approach that may enable more effective, targeted treatment tailored to individual patients.
Introduction to Pharmacology & ToxicologyNisha Mhaske
This document defines key terms related to pharmacology including:
- Pharmacy deals with the preparation of drugs for administration. Pharmacology is the study of drugs, their mechanisms and effects. Pharmacokinetics studies what the body does to drugs and pharmacodynamics studies what drugs do to the body. Other terms defined include bioavailability, pharmacogenetics, xenobiotics, orphan drugs, branded vs generic drugs, patents, and half-life.
The document discusses the role of genomics in pharmacogenomics and drug development. It defines key terms like pharmacogenomics and pharmacogenetics. It explains how genomics technologies can help optimize drug efficacy and minimize toxicity by identifying genetic variations that influence individual drug responses. Genomic information from the human genome project can aid drug target identification and reduce bottlenecks in development. Single nucleotide polymorphisms are discussed as the most common genetic variations affecting drug metabolism. The applications of pharmacogenomics in precision medicine to improve drug safety and efficacy are summarized.
THE PURPOSE of the following sections is to give a brief description of many of the major drug classes that are important to nursing pharmacology; for drug class, we ‘ll discuss one prototype drug and examine it for information about warnings, indications, administration, and more; nurses, however, should seek out detailed information about individual drugs, as the prototype cannot be assumed to provide comprehensive information on other drugs in the same class; underline=preferred administration route
This document summarizes key points about pharmacology and drug use during pregnancy. It discusses how drugs can potentially harm the fetus, especially during organogenesis in the first trimester. Certain drugs like alcohol and cigarettes are definitely teratogenic. Most small drugs pass through the placenta. The document then covers organogenesis, fetal development, delivery, recognizing teratogenic drugs, and provides guidance on commonly used drug classes in pregnancy like analgesics, antibiotics, anti-epileptics, and cardiovascular drugs.
This document discusses addictive behavior and the neurobiology of addiction. It defines addictive behavior as compulsive drug use despite negative consequences and craving effects beyond pain relief. It describes how drugs of abuse hijack the brain's reward system and lead to long-term changes in gene expression and neural plasticity through mechanisms like conditioning and memory formation. These changes help explain why addiction is persistent and why drug cues can trigger intense craving and relapse. The neurobiology of addiction involves dysregulation of the dopamine and other neurotransmitter systems in the brain's reward pathways.
Pharmacology for Physiotherapy Book By Padmaja Udaykumar Second Edition.Khalid Ghaznavi
Pharmacology for Physiotherapy Book
By Padmaja Udaykumar Second Edition.
This consists of a complete book version. I hope this will be helpful for you.
This document summarizes a systematic review that analyzed randomized controlled drug trials for fibromyalgia syndrome (FMS) and painful diabetic peripheral neuropathy (DPN) to determine the impact of nocebo effects on adverse events reported. The review found that nocebo effects substantially accounted for adverse events in the drug groups for both conditions. Specifically, nocebo effects accounted for 72.0% of dropouts due to adverse events in the FMS drug groups and 44.9% in the DPN drug groups. The review calls for standards to better assess and report adverse events in clinical trials to more accurately determine the risks and benefits of drug therapies.
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
This document defines adverse drug reactions and discusses their types, causes, manifestations, and prevention. It provides classifications of ADRs including Type A predictable reactions related to the drug's pharmacological effects and Type B unpredictable reactions like allergies. The document outlines various organ-specific ADRs and roles of pharmacists in monitoring ADRs. It emphasizes the importance of pharmacovigilance in detecting, understanding, and preventing adverse drug effects.
Drug standards and legislation are governed by laws in every country. Internationally, the first law to regulate drugs was passed in 1906 requiring drugs be free of adulterants. The Food, Drug and Cosmetic Act of 1938 required all drugs be tested for safety and approved by the FDA for marketing. The Kefauver-Harris Amendments of 1962 were passed after thalidomide caused birth defects, requiring increased drug testing. In Pakistan, several acts have been passed over time to regulate drugs including the Poisonous Act of 1919, Dangerous Drugs Act of 1930, and Pharmacy Act of 1967. The Drug Act of 1976 regulates the pharmaceutical industry and drug quality and safety.
This document provides an overview of homeopathy, including its history, mechanisms, research evidence, and applications for issues related to lactation and pediatrics. It discusses Samuel Hahnemann's development of homeopathy in the 18th century, various hypotheses for its mechanisms of action, research on its effects in animals and humans, and some studies on its use for acute infections, mastitis, gastrointestinal issues, and lactation pain in children and animals.
This document discusses drug therapy in geriatrics. It begins by listing common drug classes used to treat various conditions in elderly patients, including antibiotics, antiallergics, antiasthmatics, and antihypertensives. It then discusses several age-related changes to pharmacokinetic and pharmacodynamic processes in geriatric patients. These changes can impact drug absorption, distribution, metabolism, and excretion. It also notes an increased risk of drug interactions and adverse reactions in elderly patients due to polypharmacy and physiological changes. Finally, it discusses the role of pharmacists in optimizing drug therapy for geriatric patients.
PERSONALIZED MEDICINE AND PHARMACOGENETICSAravindgowda6
This document discusses personalized medicine and pharmacogenetics. It defines personalized medicine as tailoring medical treatment to an individual's characteristics. Pharmacogenetics is the study of how genetic differences influence variability in drug responses. The document outlines how genetic polymorphisms can impact drug metabolism and efficacy through variations in phase I and phase II drug metabolizing enzymes. It also categorizes different types of patients who may benefit from personalized medicine approaches based on factors like age, gender, medical conditions, and genetics.
The document discusses important considerations for pediatric drug handling. It covers pharmacokinetic parameters like absorption, distribution, metabolism, and excretion that differ in children compared to adults due to developmental changes. The document emphasizes the need for pediatric clinical trials to determine appropriate drug dosages, formulations, and administration methods for children of different ages. Monitoring growth, vital signs, and laboratory parameters is also important for safe drug therapy in children.
Pharmacogenomics- a step to personalized medicinesApusi Chowdhury
Pharmacogenomics aims to optimize drug therapy based on a patient's genotype to maximize efficacy and minimize adverse effects. It involves studying how genetic factors influence individual responses to drugs in terms of absorption, distribution, metabolism, and excretion. Genetic polymorphisms like SNPs that occur in over 1% of the population can impact a drug's effects. Pharmacogenomic testing identifies biomarkers related to drug metabolism and targets to determine effective treatments and dosages for patients. While it holds promise for improving drug development and personalized medicine, limitations include insufficient validation and high costs.
The document discusses key concepts related to pharmaceutical dosage forms including:
1) It defines drug and dosage form, noting that dosage form denotes the method of delivery into the biological system.
2) It explains that most drugs are not administered in pure form, but are converted into suitable preparations using excipients before being given to patients.
3) The importance of choosing the proper dosage form is that it affects how the drug is administered and how effectively it can treat a medical condition.
The document discusses brain tonics and their use in improving memory and brain function. It defines brain tonics as natural remedies that improve concentration, mood, and memory problems. Brain tonics contain herbs that enhance neurotransmitters and improve blood flow to the brain, supplying nutrients. They are useful for conditions like Alzheimer's disease and lack of concentration. Alzheimer's causes memory loss and other cognitive issues due to plaques and tangles damaging brain cells. Brain tonics support brain health and function by promoting cellular equilibrium in the nervous system.
This document discusses the role of automation and robotics in the drug discovery process. It outlines how robotics are used at various stages including screening compound collections, chemical synthesis, and purification. The use of robotics allows for faster, more consistent, and more cost-effective experimentation. It enables high-throughput experimentation by automating repetitive tasks, improving yields, and allowing scientists to synthesize and purify thousands of compounds. The key types of industrial robots used are Cartesian, SCARA, and articulated robots, each with advantages for different applications. Automation has significantly improved the drug discovery process by enhancing reproducibility, purity and efficiency.
An Abbreviated New Drug Application (ANDA) contains data to allow the FDA to review and approve a generic drug. The ANDA establishes that the generic is bioequivalent to the reference drug through comparative dissolution or bioequivalence testing.
The FDA reviews the ANDA for bioequivalence, chemistry and manufacturing controls, microbiology, and labeling. If deficiencies are identified, the applicant is notified. If all aspects are acceptable, an approval or tentative approval is issued pending any patent issues. The generic can be marketed once all review steps are successfully completed.
The document provides information about various herbs that can be used as brain tonics to improve memory and brain function. It discusses herbs like Bacopa monnieri, Centella asiatica, Withania somnifera, Glycyrrhiza glabra, and their uses as brain tonics. It also provides a formulation of a brain tonic combining several of these herbs and discusses their chemical constituents and the benefits they provide for memory, concentration, brain health, and reducing stress and anxiety.
This document outlines the requirements and guidelines for conducting clinical trials and obtaining permission to import or manufacture new drugs in India. It discusses the need to frame guidelines for clinical research and regulation of new drugs. Key points include that clinical trials require permission from the licensing authority and approval from ethics committees. Sponsors must submit various data on the drug and trials must be conducted according to Good Clinical Practice guidelines. Informed consent is required from all subjects and safety of subjects must be protected at all stages of the drug development and approval process. Trials generally proceed through Phases I-III to evaluate safety, efficacy, and optimal dosing.
it contain some production techniques of transgenic animals with some examples and utility in drug development (available transgenic animals model of drug and their activity).
Applications and uses in different field
Another techniques like transposons and knock-out & knock-in discussed later
Back Rapid lead compounds discovery through high-throughput screeningrita martin
High-throughput screening process are used by today most of the drug discovery industries, this process helps pharmaceutical researches to make drug discovery process faster and also increase the quality and quantity of drugs production. This process in combination with robotics, data processing and control software, liquid handling devices and sensitive detectors allows a researcher to quickly conduct millions of chemical, genetic or pharmacological tests
High throughput screening (HTS) at iNovaciaiNovacia AB
iNovacia offers high quality high-throughput screening services supported by a compound collection and screening libraries of highest international standards. iNovacia has a broad experience with all major target families and assay types.
The high throughput screening is the first step of the docking or computational method of drug discovery. This slide will help you to understand the basic things in HTVS.
progestins pharmacology and different forms of it............................................................................................................................................................................................................................................
High Throughput Screening (HTS) is a drug discovery process that uses automation to quickly assay a large number of compounds against biological or biochemical targets to identify potential drug candidates. Key aspects of HTS include testing compounds in microtiter plates with 96, 384, or 1536 wells using assays like cell-based, enzyme, or tissue response tests. HTS allows for high speed, sensitivity, and reproducibility in screening large libraries of compounds cost effectively. Detection methods used in HTS include spectroscopy, chromatography, calorimetry, and microscopy.
How To Add Power Point Presentations To Bloggerguest66ae43
The document provides steps for adding a PowerPoint presentation hosted on SlideShare.net to a Blogger.com blog. The steps are to first create and upload the presentation to SlideShare.net, then copy the embed code from SlideShare.net and paste it into a new blog post on Blogger.com and publish the post so the presentation embeds and can be viewed on the blog.
Transgenic animals are produced by inserting foreign genes into their genomes using recombinant DNA methodology. This allows for increased growth, improved disease resistance, and other benefits. However, it can also lead to unintended effects if the inserted gene has multiple functions or causes mutations. Common methods to create transgenic animals include embryonic stem cell methods, pronuclear injection, and retrovirus-mediated gene transfer. Examples include transgenic mice, cows, fish, sheep, and monkeys.
Pharmacogenomics is the study of how an individual's genetic profile affects their response to medications. It aims to provide the right drug at the right dose for the right patient by understanding genetic factors. Current applications include testing for genetic variants before prescribing certain drugs to avoid bad reactions. Challenges include accounting for both genetic and environmental influences on drug responses and protecting patient privacy. As understanding and technologies improve, pharmacogenomics may help develop new drugs and reduce trial-and-error prescribing.
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics Zohaib HUSSAIN
Introduction
With the information available about human genome and human proteome, it is now well understood that there are a lot of variations between individuals. These minor variations account for many differences like adverse drug reactions, which are responsible for many hospitalizations and casualties. The observed variable effect of drug is due to difference in sensitivity as some people need higher dose and some need lower dose to get similar therapeutic effect, but in some people drug has no therapeutic effects and in some it shows strong adverse reactions.
Pharmacogenomics leads to more personalized drug therapy by understanding how an individual's genetics affects their response to medications. Variations in genes can impact drug receptors, metabolism, and other factors. Understanding these genetic differences could allow doctors to prescribe safer and more effective medications at the right dose for each patient.
Pharmacogenomics is the study of how an individual's genetic inheritance affects their body's response to drugs. It combines knowledge of genetics with pharmacology to develop tailored treatments for individuals based on their genetic makeup. The goal is to understand how genetic variations influence drug metabolism and response in order to optimize drug efficacy and safety for each patient. Pharmacogenomics holds promise for more powerful and safer medications, better screening for disease, and improvements in the drug development process through a more personalized approach to medicine. However, challenges remain in fully realizing this potential due to the complexity of genetic variations and interactions.
DDS personalised medicines M.Pharma 1st Sem Pharmaceutics.pptxkushaltegginamani18
The document discusses personalized medicines and customized drug delivery systems. It defines personalized medicine as using genetic profiling and other individual patient characteristics to guide medical treatment. Customized drug delivery systems aim to optimize drug therapy for each patient by controlling dosage and delivery through technologies like bioelectronic medicines, 3D printing of pharmaceuticals, and telepharmacy.
Pre-discovery
Understand the disease
Target Identification
Choose a molecule to target with a drug
Target Validation
Test the target and confirm its role in the disease
Drug Discovery
Find a promising molecule (a “lead compound”)
that could become a drug
1. The document discusses the concepts of pharmacogenomics and ayurgenomics. Pharmacogenomics examines how genetics affect individual responses to medications, while ayurgenomics studies the correlation between ayurvedic concepts like doshas and prakriti with the human genome.
2. Early studies found correlations between certain human leukocyte antigen gene variants and specific ayurvedic prakriti types. More recent research examined gene expression differences between kapha and pitta prakriti types in relation to high altitude adaptation.
3. Ayurgenomics offers a way to bridge traditional ayurvedic medicine and modern genetics by providing a scientific understanding of basic ayurvedic concepts and incorporating ayurved
This document discusses personalized medicine, which aims to provide the right treatment for each individual patient based on their genetic profile. It defines personalized medicine as tailoring medical treatment to each patient's characteristics, needs and preferences. The development of genomic sequencing allows for more precise treatment by understanding how genetic variations impact drug metabolism and response. Pharmacogenomics studies how DNA and RNA variations affect drug effectiveness. Implementing personalized medicine through genetic testing can help reduce disease burden by improving prevention, treatment and healthcare costs while minimizing risks.
Pharmacogenomics is the branch of biochemistry in which study how an individual’s genetic inheritance affects the body response to drug. Pharmacogenomics is the intersection of genetics and pharmaceutical industry.
In this presentation a brief note is given about what is pharmacogenomics. Why different drugs work differently in different people. today pharmacogenomics, future of pharmacogenomics. also describe the future of pharmacogenomics. challenges which have to pharmacogenomics.
Pharmacology and toxicology are the study of the effects of drugs and chemicals on living organisms. A toxicologist examines how substances cause adverse health effects on humans, animals and the environment. The history of pharmacology involved early experimentation with animals to determine drug actions. Toxicologists work in various areas including mechanistic toxicology to understand disease mechanisms, descriptive toxicology for toxicity testing, regulatory toxicology for rulemaking, and translational toxicology applying basic research to patients. Their work assesses chemical risks and ensures product and environmental safety.
INTRODUCTION
What is pharmacogenomics
History
Principle
So what’s new about pharmacogenomics?
single nucleotide polymorphism (SNP)?
Genes commonly involved in pharmacogenomic drug metabolism and response
The anticipated benefits of pharmacogenomics
Pharmacogenetics Research/Database Program
Some of the barriers to using pharmacogenomics
Conclusion
References
Dr. Debasish Pradhan is a senior faculty of pharmacology who discusses the goals of pharmacogenomics which are to optimize drug therapy and ensure maximum efficacy with minimal adverse effects by moving away from trial-and-error prescribing and instead considering a patient's genes and functionality. Pharmacogenomics uses genotyping, exome, or whole genome sequencing as inputs to achieve better treatment outcomes and minimize toxicities and adverse drug reactions.
Pharmacology Theory_Introduction & Routes of Administration.pptxAbhishekSharma921450
This document provides an introduction to the key concepts in pharmacology. It defines terms like pharmacy, pharmacology, toxicology, pharmacodynamics, pharmacokinetics and discusses the scope and applications of pharmacology. It also covers important topics like routes of drug administration, drug nomenclature, factors affecting drug action and authentic sources of drug information.
clinical and preclinical approaches to drug discovery.Here we mainly deals with preclinical approaches, ie. Pharmacological approach and toxicological approach
Pharmacology is the study of how drugs interact with biological systems and affect function. Key areas include pharmacodynamics, which studies drug effects on biological systems, and pharmacokinetics, which studies the absorption, distribution, metabolism, and excretion of drugs. Pharmacology aims to understand drug actions at the molecular level through studying drug interactions with receptors and cellular signaling pathways. It provides a scientific framework for medicine development and safety testing of new drugs.
PH 1.1 DEFINE and DESCRIBE the Principles of Pharmacology and Pharmacotherape...Dr SURENDRA BOUDDH
This document provides definitions and principles related to pharmacology and pharmacotherapeutics. It defines key terms like pharmacology, pharmacotherapeutics, drug, and medicine. It describes the principles of pharmacology as how exogenously administered drugs interact with the living system, which depends on pharmacokinetics of how the body affects the drug and pharmacodynamics of how the drug affects the body. Principles of pharmacotherapeutics include applying pharmacological knowledge together with disease knowledge for diagnosis, prevention and treatment. Factors like age, sex, genetics, and route of administration can modify a drug's effects.
Pharmacogenomics is the study of how genes affect individual responses to drugs. It combines pharmacology and genomics to develop safe and effective personalized medications and dosages based on a person's genetic makeup. The goal is to improve treatment outcomes by predicting drug effectiveness and reducing adverse reactions. Challenges include implementing genetic tests in clinical practice and addressing cost, ethical and legal issues. Future applications include developing tailored drugs for many diseases and faster, more targeted clinical trials through biomarkers.
Special topic genomics and personalized medicinewatsonma12
This document discusses the emerging field of personalized medicine and how genomics is enabling more targeted medical treatments. It provides examples of how genetic testing can identify patients who will benefit from certain drugs, like Herceptin for breast cancer patients with high levels of the HER-2 gene. The document also outlines some technical, social, and ethical challenges to widespread adoption of personalized medicine, such as improving genetic testing technologies, educating physicians, and preventing discrimination based on genetic information.
This document provides an introduction to pharmacology. It discusses that pharmacology is the study of drugs and their interaction with living systems. The two main divisions of pharmacology are pharmacodynamics, which refers to what the drug does to the body, and pharmacokinetics, which refers to what the body does to the drug. It also discusses key concepts in pharmacology including the essential drug concept, clinical pharmacology, and how pharmacology relates to other fields like pharmacy, toxicology, and biotechnology.
Clinical trials involve several phases of testing new medical interventions in human subjects to generate safety and efficacy data. Phase 0 trials involve microdosing to determine pharmacokinetic and pharmacodynamic properties. Phase I trials use small patient groups to determine maximum tolerated dose. Phase II trials screen for activity, safety and feasibility in larger patient groups. Phase III trials are large randomized controlled trials that compare new treatments to standard treatments. Phase IV trials monitor long-term safety and effectiveness if the treatment is approved. The goal is to progress from exploratory to definitive assessment through each phase to provide evidence for approval or non-approval of the new medical intervention.
This document outlines the rules and regulations for conducting clinical trials and importing or manufacturing new drugs in India. It discusses the various forms and permissions required, including Form 44 for new drug approval and Form 12 for importing study drugs. It also describes the responsibilities of sponsors, investigators, and ethics committees. The document explains the different phases of clinical trials from human pharmacology to post-marketing surveillance. It lists the data that must be submitted with applications and included in clinical study reports.
The document outlines procedures for identifying, recording, and reporting adverse reactions and serious adverse reactions that may occur during clinical trials. It defines key terms like adverse events, adverse reactions, serious adverse reactions, and suspected unexpected serious adverse reactions. It describes the responsibilities of investigators and sponsors in assessing adverse events, reporting serious adverse reactions to licensing authorities within 14 days, and ensuring medical care for subjects experiencing adverse reactions. Flowcharts are provided to illustrate the processes for identifying adverse reactions and determining expectedness and implications for reporting.
The document is a seminar paper on tests for teratogenicity presented by Sumangali M to fulfill requirements for a Master of Pharmacy degree from Jawaharlal Nehru Technological University, Hyderabad. It includes definitions of teratogenicity and teratology, principles of teratology, descriptions of critical periods in fetal development, and discussions of several known historical teratogens including thalidomide, Accutane, diethylstilbestrol, and alcohol.
This study examined the effects of administering vasopressin at different times of day on adrenocorticotropic hormone (ACTH) levels in humans. Volunteers received increasing doses of vasopressin intravenously either in the evening at 2200h and morning at 0700h, or with times reversed. ACTH levels increased with higher vasopressin doses. Morning ACTH responses were greater than evening responses, as measured by peak levels, area under the curve, and sensitivity of the dose response. The findings suggest vasopressin stimulation of ACTH can be used to assay endogenous corticotropin-releasing factor (CRF), and that CRF levels have a diurnal rhythm in the
This document compares different methods for assaying hyaluronidase enzyme preparations, including a biological skin diffusion assay and two physicochemical assays (viscosimetric and turbidimetric). Seven different hyaluronidase preparations were assayed using all three methods. The results showed reasonable correlation between the biological assay and viscosimetric assay, but poorer correlation with the turbidimetric assay. The nature of the hyaluronate substrate did not significantly affect the viscosimetric assay results for most preparations, except one streptococcal preparation which showed higher activity on purified substrate.
This document describes a technique for bioassaying histamine in the presence of prostaglandins using an Amberlite XAD-2 column. The column removes prostaglandins, rabbit aorta contracting substance, and possibly slow reacting substance of anaphylaxis, but allows histamine to pass through. Two banks of bioassay organs (rabbit aorta strip, rat stomach strip, guinea pig ileum) are used, with one bank above the column and one below. This allows accurate measurement of histamine levels in samples also containing prostaglandins and other substances that interfere with histamine bioassay. The method was tested using effluent from shocked, perfused guinea pig lungs and showed improved accuracy
This document describes modifications made to the bioassay method for quantitatively measuring acetylcholine. The modifications include developing a simple, inexpensive photoelectric apparatus that provides more reliable results than the standard smoked drum method. The apparatus uses a photoelement connected by lever to a muscle bath, so muscle contractions alter the light falling on the photoelement and allow direct measurement of contraction strength. Calibration curves demonstrate the apparatus provides linear measurements of acetylcholine levels between 50-200 ng for frog muscle and 5-20 ng for leech muscle. The modified method is described as being as sensitive as standard assays but providing easier, more reproducible quantification of acetylcholine.
1) Two techniques, bioassay and radioimmunoassay, are used to measure levels of the antidiuretic hormone arginine vasopressin (AVP) but radioimmunoassay is more sensitive and specific.
2) Basal circulating levels of AVP are very low, below the detection limit of most assays, so urinary concentrations are studied instead as a proxy for plasma levels. Patterns of urinary excretion correlate with known stimuli and disorders of AVP secretion.
3) The two techniques generally show close correlation, though radioimmunoassay sometimes detects slightly higher levels, possibly due to non-specific interference rather than biologically inactive fragments.
This document describes an enzymatic assay kit for quantitatively measuring acetylcholine concentration in biological samples. The kit uses acetylcholinesterase to hydrolyze acetylcholine to choline, which is then oxidized to produce a product that reacts with a dye to generate a color (colorimetric assay) or fluorescence (fluorimetric assay). The intensity is directly proportional to the acetylcholine concentration and can be used to calculate the amount in samples. The kit provides a simple, direct, and high-throughput method for acetylcholine detection with applications in drug discovery and studies of acetylcholine metabolism.
The document summarizes the principles of drug discovery, including the following key points:
1) Drug discovery is a lengthy, expensive, and inefficient process involving target identification, screening, preclinical testing, and clinical trials that can take over 10 years from initial compound to approved drug.
2) Natural products, especially from plants, microbes, and marine organisms, have historically been an important source of leads for drug discovery due to their chemical diversity.
3) The modern drug discovery process involves high-throughput screening of large libraries of synthetic compounds and natural products to identify initial hits, which are then optimized in the hit-to-lead phase through medicinal chemistry and further testing.
The document discusses the principles and process of drug discovery, which involves identifying a target, screening compounds, preclinical testing, and clinical trials. It takes an average of 12-15 years and $600-800 million to bring a new drug to market. Key stages include target identification and validation, screening compounds through various techniques, preclinical studies in animals, and clinical trials in phases I-III to test safety and efficacy in humans. Novel approaches like microarrays, peptidomimetics, pharmacogenomics, and cheminformatics can aid the drug discovery process.
This document discusses new biological targets for drug development. It begins by defining biological targets and describing common targets such as G protein-coupled receptors, enzymes, and ligand-gated ion channels. Specific examples of new targets discussed include macrophages for HIV drugs, proteins involved in insulin signaling for diabetes therapies, and the cytokine IL-23 for inflammatory bowel disease. The document also mentions research into new targets for skin cancer, cardiovascular disease, and general efforts to identify novel drug targets from biological systems.
This document summarizes a seminar on pharmacogenomics and its promise for personalized medicine. Pharmacogenomics uses DNA analysis to target drugs to specific patient populations based on their genetic makeup. It aims to increase drug safety and efficacy by individualizing treatment. Recent research has applied pharmacogenomic approaches to develop personalized therapies for conditions like HIV, cancer, cardiovascular disease, and depression. While pharmacogenomics faces scientific hurdles, it has the potential to enhance drug discovery, development, and outcomes by identifying genetic factors influencing drug targets and individual responses.
Bioassays are used to determine the potency of drugs when chemical assays are not available or sufficient. They involve comparing the biological effects of a test drug to a reference standard. Three common bioassay methods include end point assays which measure the threshold dose, matching assays which bracket test doses between standard doses, and graphical assays which plot dose-response curves. Important drugs assayed include digitalis, adrenaline, acetylcholine, and antagonists. Assays use tissues like cat blood pressure, guinea pig ileum, rat uterus to measure relevant pharmacological effects like changes in blood pressure or muscle contraction.
The document discusses peptic ulcers, including:
1. It provides an introduction defining peptic ulcers and their locations in the stomach or duodenum.
2. It discusses the history of discoveries around Helicobacter pylori being identified as a primary cause of peptic ulcers in the 1980s.
3. It describes common symptoms of peptic ulcers such as abdominal pain that is often relieved by food for duodenal ulcers but worsened by food for gastric ulcers.
This document summarizes various drugs used to treat peptic ulcers caused by excess stomach acid and Helicobacter pylori infection. It discusses histamine antagonists like cimetidine that block acid production. Proton pump inhibitors like omeprazole irreversibly block the acid pump. Sucralfate forms a protective barrier over ulcers. Antibiotics can eliminate H. pylori infections. Lifestyle changes and antacids are also mentioned.
This document summarizes salivary markers of systemic diseases. Saliva is a non-invasive diagnostic fluid that has several advantages over blood, including being easy to collect. Saliva contains biomarkers that can indicate diseases like Sjogren's syndrome, cystic fibrosis, diabetes, and various cancers. New technologies are being developed to more precisely measure salivary proteomes, transcriptomes, and other biomarkers to diagnose diseases from saliva. Saliva is a promising diagnostic fluid that reflects the body's health status in a non-invasive way.
The patch clamp technique allows studying single or multiple ion channels in cells. Developed in the 1970s-1980s by Sakmann and Neher, it provides a way to insert an electrode into a cell and change its intracellular fluid while creating an impermeable seal. There are different types of patch clamp methods, and it is used to evaluate drug interactions with ion channels and measure properties like current, conductance, and dose response curves. Recent developments aim to improve techniques like intracellular perfusion and throughput.
Ivanti’s Patch Tuesday breakdown goes beyond patching your applications and brings you the intelligence and guidance needed to prioritize where to focus your attention first. Catch early analysis on our Ivanti blog, then join industry expert Chris Goettl for the Patch Tuesday Webinar Event. There we’ll do a deep dive into each of the bulletins and give guidance on the risks associated with the newly-identified vulnerabilities.
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slackshyamraj55
Discover the seamless integration of RPA (Robotic Process Automation), COMPOSER, and APM with AWS IDP enhanced with Slack notifications. Explore how these technologies converge to streamline workflows, optimize performance, and ensure secure access, all while leveraging the power of AWS IDP and real-time communication via Slack notifications.
HCL Notes und Domino Lizenzkostenreduzierung in der Welt von DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-und-domino-lizenzkostenreduzierung-in-der-welt-von-dlau/
DLAU und die Lizenzen nach dem CCB- und CCX-Modell sind für viele in der HCL-Community seit letztem Jahr ein heißes Thema. Als Notes- oder Domino-Kunde haben Sie vielleicht mit unerwartet hohen Benutzerzahlen und Lizenzgebühren zu kämpfen. Sie fragen sich vielleicht, wie diese neue Art der Lizenzierung funktioniert und welchen Nutzen sie Ihnen bringt. Vor allem wollen Sie sicherlich Ihr Budget einhalten und Kosten sparen, wo immer möglich. Das verstehen wir und wir möchten Ihnen dabei helfen!
Wir erklären Ihnen, wie Sie häufige Konfigurationsprobleme lösen können, die dazu führen können, dass mehr Benutzer gezählt werden als nötig, und wie Sie überflüssige oder ungenutzte Konten identifizieren und entfernen können, um Geld zu sparen. Es gibt auch einige Ansätze, die zu unnötigen Ausgaben führen können, z. B. wenn ein Personendokument anstelle eines Mail-Ins für geteilte Mailboxen verwendet wird. Wir zeigen Ihnen solche Fälle und deren Lösungen. Und natürlich erklären wir Ihnen das neue Lizenzmodell.
Nehmen Sie an diesem Webinar teil, bei dem HCL-Ambassador Marc Thomas und Gastredner Franz Walder Ihnen diese neue Welt näherbringen. Es vermittelt Ihnen die Tools und das Know-how, um den Überblick zu bewahren. Sie werden in der Lage sein, Ihre Kosten durch eine optimierte Domino-Konfiguration zu reduzieren und auch in Zukunft gering zu halten.
Diese Themen werden behandelt
- Reduzierung der Lizenzkosten durch Auffinden und Beheben von Fehlkonfigurationen und überflüssigen Konten
- Wie funktionieren CCB- und CCX-Lizenzen wirklich?
- Verstehen des DLAU-Tools und wie man es am besten nutzt
- Tipps für häufige Problembereiche, wie z. B. Team-Postfächer, Funktions-/Testbenutzer usw.
- Praxisbeispiele und Best Practices zum sofortigen Umsetzen
Your One-Stop Shop for Python Success: Top 10 US Python Development Providersakankshawande
Simplify your search for a reliable Python development partner! This list presents the top 10 trusted US providers offering comprehensive Python development services, ensuring your project's success from conception to completion.
Have you ever been confused by the myriad of choices offered by AWS for hosting a website or an API?
Lambda, Elastic Beanstalk, Lightsail, Amplify, S3 (and more!) can each host websites + APIs. But which one should we choose?
Which one is cheapest? Which one is fastest? Which one will scale to meet our needs?
Join me in this session as we dive into each AWS hosting service to determine which one is best for your scenario and explain why!
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
Driving Business Innovation: Latest Generative AI Advancements & Success StorySafe Software
Are you ready to revolutionize how you handle data? Join us for a webinar where we’ll bring you up to speed with the latest advancements in Generative AI technology and discover how leveraging FME with tools from giants like Google Gemini, Amazon, and Microsoft OpenAI can supercharge your workflow efficiency.
During the hour, we’ll take you through:
Guest Speaker Segment with Hannah Barrington: Dive into the world of dynamic real estate marketing with Hannah, the Marketing Manager at Workspace Group. Hear firsthand how their team generates engaging descriptions for thousands of office units by integrating diverse data sources—from PDF floorplans to web pages—using FME transformers, like OpenAIVisionConnector and AnthropicVisionConnector. This use case will show you how GenAI can streamline content creation for marketing across the board.
Ollama Use Case: Learn how Scenario Specialist Dmitri Bagh has utilized Ollama within FME to input data, create custom models, and enhance security protocols. This segment will include demos to illustrate the full capabilities of FME in AI-driven processes.
Custom AI Models: Discover how to leverage FME to build personalized AI models using your data. Whether it’s populating a model with local data for added security or integrating public AI tools, find out how FME facilitates a versatile and secure approach to AI.
We’ll wrap up with a live Q&A session where you can engage with our experts on your specific use cases, and learn more about optimizing your data workflows with AI.
This webinar is ideal for professionals seeking to harness the power of AI within their data management systems while ensuring high levels of customization and security. Whether you're a novice or an expert, gain actionable insights and strategies to elevate your data processes. Join us to see how FME and AI can revolutionize how you work with data!
leewayhertz.com-AI in predictive maintenance Use cases technologies benefits ...alexjohnson7307
Predictive maintenance is a proactive approach that anticipates equipment failures before they happen. At the forefront of this innovative strategy is Artificial Intelligence (AI), which brings unprecedented precision and efficiency. AI in predictive maintenance is transforming industries by reducing downtime, minimizing costs, and enhancing productivity.
Main news related to the CCS TSI 2023 (2023/1695)Jakub Marek
An English 🇬🇧 translation of a presentation to the speech I gave about the main changes brought by CCS TSI 2023 at the biggest Czech conference on Communications and signalling systems on Railways, which was held in Clarion Hotel Olomouc from 7th to 9th November 2023 (konferenceszt.cz). Attended by around 500 participants and 200 on-line followers.
The original Czech 🇨🇿 version of the presentation can be found here: https://www.slideshare.net/slideshow/hlavni-novinky-souvisejici-s-ccs-tsi-2023-2023-1695/269688092 .
The videorecording (in Czech) from the presentation is available here: https://youtu.be/WzjJWm4IyPk?si=SImb06tuXGb30BEH .
FREE A4 Cyber Security Awareness Posters-Social Engineering part 3Data Hops
Free A4 downloadable and printable Cyber Security, Social Engineering Safety and security Training Posters . Promote security awareness in the home or workplace. Lock them Out From training providers datahops.com
Best 20 SEO Techniques To Improve Website Visibility In SERPPixlogix Infotech
Boost your website's visibility with proven SEO techniques! Our latest blog dives into essential strategies to enhance your online presence, increase traffic, and rank higher on search engines. From keyword optimization to quality content creation, learn how to make your site stand out in the crowded digital landscape. Discover actionable tips and expert insights to elevate your SEO game.
Generating privacy-protected synthetic data using Secludy and MilvusZilliz
During this demo, the founders of Secludy will demonstrate how their system utilizes Milvus to store and manipulate embeddings for generating privacy-protected synthetic data. Their approach not only maintains the confidentiality of the original data but also enhances the utility and scalability of LLMs under privacy constraints. Attendees, including machine learning engineers, data scientists, and data managers, will witness first-hand how Secludy's integration with Milvus empowers organizations to harness the power of LLMs securely and efficiently.
Skybuffer SAM4U tool for SAP license adoptionTatiana Kojar
Manage and optimize your license adoption and consumption with SAM4U, an SAP free customer software asset management tool.
SAM4U, an SAP complimentary software asset management tool for customers, delivers a detailed and well-structured overview of license inventory and usage with a user-friendly interface. We offer a hosted, cost-effective, and performance-optimized SAM4U setup in the Skybuffer Cloud environment. You retain ownership of the system and data, while we manage the ABAP 7.58 infrastructure, ensuring fixed Total Cost of Ownership (TCO) and exceptional services through the SAP Fiori interface.
Skybuffer AI: Advanced Conversational and Generative AI Solution on SAP Busin...Tatiana Kojar
Skybuffer AI, built on the robust SAP Business Technology Platform (SAP BTP), is the latest and most advanced version of our AI development, reaffirming our commitment to delivering top-tier AI solutions. Skybuffer AI harnesses all the innovative capabilities of the SAP BTP in the AI domain, from Conversational AI to cutting-edge Generative AI and Retrieval-Augmented Generation (RAG). It also helps SAP customers safeguard their investments into SAP Conversational AI and ensure a seamless, one-click transition to SAP Business AI.
With Skybuffer AI, various AI models can be integrated into a single communication channel such as Microsoft Teams. This integration empowers business users with insights drawn from SAP backend systems, enterprise documents, and the expansive knowledge of Generative AI. And the best part of it is that it is all managed through our intuitive no-code Action Server interface, requiring no extensive coding knowledge and making the advanced AI accessible to more users.
Salesforce Integration for Bonterra Impact Management (fka Social Solutions A...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on integration of Salesforce with Bonterra Impact Management.
Interested in deploying an integration with Salesforce for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.